Item 8.01 Other Events

On January 25, 2021, DURECT Corporation issued a press release announcing that it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits





    99.1   Press Release of DURECT Corporation dated January 25, 20  21
    104  Cover Page Interactive Data File (embedded within the Inline XBRL
         document)












                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses